ASIT biotech s.a. (formerly Biotech Tools) is a clinical stage biopharmaceutical company focused on the development and future commercialization of a range of breakthrough immunotherapy products for the treatment of allergies, based on its ASIT+TM technology platform.
ASIT biotech was founded in May 1997 as a spin-off company of the Université Libre de Bruxelles. Thierry LEGON has served as ASIT biotech Chief Executive Officer (CEO) since 2000. ASIT biotech is headquartered in Belgium close to Brussels Airport.
ASIT biotech has built-up a network of experts qualified in product development and manufacturing, preclinical and clinical development, regulatory, marketing strategy, market access, finance, business development, licensing and Merger and Acquisition (M&A). ASIT biotech development is based on the outsourcing of the manufacturing, the preclinical and clinical development to worldwide renowned universities and medical organizations.
|2010||BTT-gpASIT004 Phase I study: demonstration of safety and immunogenicity of subcutaneous administration of gp-ASIT+TM, a product candidate for the treatment of grass pollen rhinitis|
|2012||BTT-gpASIT006 Phase IIa study: demonstration of a one year lasting effect of gp-ASIT+TM, a product candidate for the treatment of grass pollen rhinitis|
BTT-gpASIT007 Phase IIa study: proof of concept reached by the demonstration of the clinical effect of gp-ASIT+TM on an allergen provocation test
ASIT biotech rises the funds necessary to run the first phase III clinical study with gp-ASIT+TM